Ozempic Shows Potential for Alcohol Addiction in Trial

(MedPage Today) — Weekly treatment with low doses of the GLP-1 receptor agonist semaglutide (Ozempic) reduced alcohol consumption and craving in adults with alcohol use disorder (AUD), a phase II randomized trial showed.
At 9 weeks, semaglutide…